



Via E-Mail ([AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov))

December 17, 2021

TJ Donovan  
Attorney General  
Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609

Re: Notice of New Prescription Drug to Market

Dear Mr. Donovan:

Pursuant to 18 VT. Stat. Ann. § 4637(b), this letter shall serve as notice that BioMarin Pharmaceutical Inc. ("BioMarin") released VOXZOGO® (NDCs 68135-0082-36, 68135-0119-66, and 68135-0181-93), "a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program" on December 17, 2021.

18 VT. Stat. Ann. § 4637 does not currently define "release of the drug in the commercial market." Further, BioMarin is not aware of any guidance issued by the Vermont Attorney General's Office or any Vermont regulation that defines "release of the drug in the commercial market" for the purpose of 18 VT. Stat. Ann. § 4637. BioMarin interprets "release of the drug in the commercial market" to mean the anticipated availability date BioMarin communicates to a pricing compendia.

Please contact Wil Myers, Corporate Counsel, at [statepricetransparency@bmrn.com](mailto:statepricetransparency@bmrn.com) if you have any questions.

Sincerely,



DocuSigned by:  
A handwritten signature in black ink, appearing to read "Chuck Bucklar".

B72C7009800A4CC...  
Chuck Bucklar  
SVP, Commercial Operations North America